Hepatiq Inc.

The liver is a remarkable organ. When injured by viruses, alcohol, or fat, all of which cause fibrosis, the liver fights back - regenerating tissue and boosting blood flow. Yet, currently used liver tests measure only fibrosis and the resulting scar tissue.  Fibrosis tests tell us the extent of liver damage, but miss the regeneration and perfusion that help compensate for fibrosis damage.  And they don’t tell us how much healthy, working liver is actually left.  
  
That is why two patients with the same fibrosis score can have very different outcomes - one stays stable for years while the other declines quickly. The difference? It’s not the fibrosis — it’s the health of the remaining liver tissue.  HEPATIQ changes the game. Using nuclear imaging and intelligent software, it measures the liver’s actual functional capacity.  And it provides a multi-dimensional physiologic stage that allows physicians to go beyond fibrosis staging.

In the landmark NIH funded, 8-year long, multi-center HALT-C trial, HEPATIQ’s PHM index outperformed all other tests in predicting outcomes two years ahead of time. Patients with low PHM had a 15X higher risk of serious complications like variceal bleeding, ascites, encephalopathy and death.  Unlike biopsy and elastography, HEPATIQ quantifies the whole liver.  No sampling errors. No assumptions. No guesswork.  If you want to predict outcomes, guide treatment, and truly understand liver health, you need HEPATIQ’s physiologic staging.